Individual factorskidney function, gastroparesis history, pancreatitis, and genetic predispositions in GLP-1 signaling pathwaysinform whether semaglutide is a good fit
serious adverse events higher but manageable
On April 1, 2026, the FDA approved orforglirpon under the brand name Foundayo to reduce excess body weight and maintain weight reduction long term in: Adults with obesity Adults with overweight and at least one weight-related medical condition Like other GLP-1s for weight loss, orforglipron is also indicated in combination with a reduced-calorie diet and increased physical activity
Theres a newer peptide called PDA, or pentadeca arginate, that has a very similar molecular structure as BPC-157, but instead of it being an acetate, its an arginate essentially just swapping out one amino acid for another
The mechanism works the same way whether a patient has elevated blood sugar or maintains normal glucose levels, making these drugs equally relevant for weight management across metabolic profiles
GLP-1 agonists reduce appetite and slow gastric emptying, which can lead to lower blood sugar levels, especially when combined with other glucose-lowering agents
